Patents Assigned to Diasorin S.p.A.
  • Patent number: 11827923
    Abstract: The invention concerns a method for detecting isothermal loop-mediated (LAMP) amplification of a target nucleic acid sequence which is based on the fluorescence resonance energy transfer (FRET) mechanism. The invention also concerns a set of oligonucleotides and a kit adapted for carrying out the LAMP-FRET method of the invention.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: November 28, 2023
    Assignee: DIASORIN S.p.A.
    Inventors: Giulia Minnucci, Riccardo Mesturini
  • Patent number: 11261257
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method. The assay is preferably a sandwich immunoassay.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 1, 2022
    Assignee: DiaSorin S.p.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli
  • Publication number: 20210340636
    Abstract: The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents, and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
    Type: Application
    Filed: July 13, 2021
    Publication date: November 4, 2021
    Applicant: DiaSorin S.p.A.
    Inventors: Chiara Brambati, Simone Bocchetta, Giulia Minnucci
  • Publication number: 20210324484
    Abstract: The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents, and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
    Type: Application
    Filed: October 23, 2020
    Publication date: October 21, 2021
    Applicant: DiaSorin S.p.A.
    Inventors: Chiara Brambati, Simone Bocchetta, Giulia Minnucci
  • Patent number: 11149320
    Abstract: The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents, and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 19, 2021
    Assignee: DiaSorin S.p.A.
    Inventors: Chiara Brambati, Simone Bocchetta, Giulia Minnucci
  • Publication number: 20210230682
    Abstract: A method of fluorescent detection of isothermal loop-mediated amplification (LAMP) of a target nucleic acid, oligonucleotides and kits thereof The invention concerns a method for detecting isothermal loop-mediated (LAMP) amplification of a target nucleic acid sequence which is based on the fluorescence resonance energy transfer (FRET) mechanism. The invention also concerns a set of oligonucleotides and a kit adapted for carrying out the LAMP-FRET method of the invention.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Applicant: DIASORIN S.p.A.
    Inventors: Giulia Minnucci, Riccardo Mesturini
  • Patent number: 10983136
    Abstract: The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: April 20, 2021
    Assignee: DiaSorin S.p.A.
    Inventors: Francesco Colotta, Fabrizio Bonelli, Frank Blocki, Claudia Zierold, Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca
  • Patent number: 10982270
    Abstract: The invention concerns a method for detecting isothermal loop-mediated (LAMP) amplification of a target nucleic acid sequence which is based on the fluorescence resonance energy transfer (FRET) mechanism. The invention also concerns a set of oligonucleotides and a kit adapted for carrying out the LAMP-FRET method of the invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: April 20, 2021
    Assignee: DiaSorin S.p.A.
    Inventors: Giulia Minnucci, Riccardo Mesturini
  • Publication number: 20210072264
    Abstract: The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: DiaSorin S.p.A.
    Inventors: Francesco Colotta, Fabrizio Bonelli, Frank Blocki, Claudia Zierold
  • Patent number: 10815539
    Abstract: The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 27, 2020
    Assignee: DiaSorin S.p.A.
    Inventors: Chiara Brambati, Simone Bocchetta, Giulia Minnucci
  • Publication number: 20200062852
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method. The assay is preferably a sandwich immunoassay.
    Type: Application
    Filed: November 12, 2019
    Publication date: February 27, 2020
    Applicant: DiaSorin S.p.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli
  • Publication number: 20200025760
    Abstract: The present invention relates to a method for detecting Zika virus (ZIKV) infection in a biological sample from a subject. The method comprises testing the sample for IgM- and IgG-ZIKV NS1 antibodies and determining the ZIKV IgM and ZIKV IgG signal intensities; and scoring the sample as positive or negative for ZIKV infection based on the combined results of such determinations. The biological sample is preferably blood, serum, plasma, cerebrospinal fluid, saliva or urine.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: DiaSorin S.p.A.
    Inventors: Fabrizio Bonelli, Tina Bunnell, James Wassenberg
  • Patent number: 10501548
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method. The assay is preferably a sandwich immunoassay.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 10, 2019
    Assignee: DiaSorin S.p.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli
  • Patent number: 10196449
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method of the invention, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method of the invention. The assay of the invention is preferably a sandwich immunoassay.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 5, 2019
    Assignee: DiaSorin S.p.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli
  • Publication number: 20180371534
    Abstract: The invention concerns a method for detecting isothermal loop-mediated (LAMP) amplification of a target nucleic acid sequence which is based on the fluorescence resonance energy transfer (FRET) mechanism. The invention also concerns a set of oligonucleotides and a kit adapted for carrying out the LAMP-FRET method of the invention.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 27, 2018
    Applicant: DIASORIN S.p.A.
    Inventors: Giulia Minnucci, Riccardo Mesturini
  • Patent number: 9938569
    Abstract: A method includes performing a nucleic acid amplification of a nucleic acid sample using a detection probe, wherein the nucleic acid amplification occurs over one or more interrogation periods, and, from the nucleic acid amplification, acquiring amplification data that indicates an amount of nucleic acid present for each of the one or more interrogation periods. The method also includes, based on the amplification data, determining a crosstalk correction value associated with a spectral neighbor to the probe to reduce spectral crosstalk from the spectral neighbor; and applying the crosstalk correction value to amplification data collected from multiplex nucleic acid amplifications of nucleic acid samples.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: April 10, 2018
    Assignee: DIASORIN S.P.A.
    Inventor: Peter D. Ludowise
  • Publication number: 20170322230
    Abstract: The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 9, 2017
    Applicant: DiaSorin S.p.A.
    Inventors: Francesco Colotta, Fabrizio Bonelli, Frank Blocki, Claudia Zierold
  • Publication number: 20170267770
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method. The assay is preferably a sandwich immunoassay.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 21, 2017
    Applicant: Diasorin S.p.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli
  • Patent number: 9725762
    Abstract: Systems and methods for processing sample processing devices. The system can include a sample processing device comprising a detection chamber, a motor configured to rotate the sample processing device about an axis of rotation, and an optical module operatively positioned relative to the sample processing device and configured to determine whether a selected volume of material is present in the detection chamber of the sample processing device. The method can include rotating the sample processing device about an axis of rotation, and determining whether a selected volume of material is present in the detection chamber, while rotating the sample processing device. In some embodiments, determining whether a selected volume of material is present can be performed by optically interrogating the detection chamber for an optical property of the material.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 8, 2017
    Assignee: Diasorin S.P.A.
    Inventors: Peter D. Ludowise, David A. Whitman, Kyle C. Armantrout, Maurice Exner, Lucien A. E. Jacky, Michelle Tabb
  • Publication number: 20150361178
    Abstract: There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method of the invention, the pH of the test sample is adjusted to 6-9 and a receptor protein comprising the Ligand Binding Domain of Vitamin D Receptor (VDR-LBD) is added to the test sample, thereby obtaining the formation of a VDR-LBD/1,25-dihydroxyvitamin D complex in which the VDR-LBD portion is conformationally changed with respect to unbound VDR-LBD. The VDR-LBD/1,25-dihydroxyvitamin D complex is then detected by means of a capture moiety which is capable of specifically binding to VDR-LBD bound to 1,25-dihydroxyvitamin D. Also disclosed are an assay kit and an antibody for carrying out the method of the invention. The assay of the invention is preferably a sandwich immunoassay.
    Type: Application
    Filed: January 27, 2014
    Publication date: December 17, 2015
    Applicant: DIASORIN S.P.A.
    Inventors: Joshua Soldo, Gregory Olson, Michael Lutterman, John Wall, Michael New, Hector Floyd Deluca, Fabrizio Bonelli